Milan-based Genenta Science, which has an experimental gene therapy for delivering interferon to tumours, has signed a multi-year manufacturing agreement with MolMed SpA in preparation for the start of clinical trials of a gene therapy for multiple myeloma.
Netherlands-based Qiagen NV, a producer of medical devices and diagnostics, is making an agreed bid for its smaller rival Exiqon A/S of Denmark for approximately €12 million in a further sign of consolidation in the global diagnostics industry.
A 2015 oncology start-up from the Netherlands has obtained €7 million in Series A financing for a technology that targets the metabolic changes in tumour cells as a way of destroying them. Gadeta BV is based on research from the University Medical Center Utrecht.
Atlantic Healthcare Plc, a UK firm specialising in gastrointestinal disorders, has raised $24 million in a private equity placement to finance the Phase 3 development of an experimental drug called alicaforsen for treating inflammatory bowel disease pouchitis.
The convergence of life science and information technology has received further validation with the launch of a new €250 million fund called Endeavour Medtech Growth LP to support medical device and digital health companies in Europe and the US.
France-based Gecko Biomedical SAS has obtained €22.5 million in equity financing from Sofinnova Partners, Bpifrance and others in order to advance its medical device for tissue reconstruction, which is based on proprietary biopolymers.
Onxeo SA, which was formed from the 2014 merger of BioAlliance Pharma SA of France and Topotarget A/S of Denmark, has completed the acquisition of DNA Therapeutics SA of France in a move that will strengthen its expertise in rare cancers.
Mercia Technologies Plc, which provides seed and follow-on funding to UK technology companies, has expanded the geographical penetration of its operations with the acquisition of Enterprise Ventures Group Ltd, a company located in the north of England.
GlaxoSmithKline Plc has signed an agreement with a service company in Germany to gain access to technology for industrialising cell and gene therapies. The two parties will also discover new chimeric antigen-receptor T (CAR T) cell therapies.
eTheRNA immunotherapies NV, a 2013 spinout from the Free University of Brussels, has raised €24 million in a Series A equity financing for the development of its TriMix-based immunotherapy for treating melanoma, breast cancer and infectious diseases.